Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Alcolea

Showing results (181-190 of 242) with videos related to

Pageof 25
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 12, 2025
Amyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapiesSara Rubio-Guerra, Isabel Sala, María Belén Sánchez-Saudinós, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 29, 2026
Peak width of skeletonized mean diffusivity reveals early and multifactorial white matter injury across sporadic and Down syndrome-associated Alzheimer's diseaseAlejandra O Morcillo-Nieto, Maria Franquesa-Mullerat, Sara E Zsadanyi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 29, 2017
Cortical microstructural changes along the Alzheimer's disease continuumVictor Montal, Eduard Vilaplana, Daniel Alcolea, et al.
NPJ Parkinson'S Disease|April 10, 2026
Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein diseaseAlena M Smith, Sara A Lorkiewicz, Burak Arslan, et al.
Nature Aging|April 28, 2023
CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panelsMarta Del Campo, Carel F W Peeters, Erik C B Johnson, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 12, 2025
Development of amyloid-negative neuropsychological norms using GAMLSSSara Rubio-Guerra, María Belén Sánchez-Saudinós, Isabel Sala, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 19, 2022
Intermediate and Expanded HTT Alleles and the Risk for α-SynucleinopathiesSergio Pérez-Oliveira, Ignacio Álvarez, Irene Rosas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 4, 2025
Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stagesMatej Perovnik, Urban Simončič, Jan Jamšek, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 6, 2020
Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patientsLorena Martín-Aguilar, Pol Camps-Renom, Cinta Lleixà, et al.
Journal of Alzheimer'S Disease : JAD|October 16, 2018
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid BiomarkersMafalda Ramos de Matos, Catarina Ferreira, Sanna-Kaisa Herukka, et al.
Pageof 25

Showing results (181-190 of 242) with videos related to

Sort By:
Pageof 25
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 12, 2025
Amyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapiesSara Rubio-Guerra, Isabel Sala, María Belén Sánchez-Saudinós, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 29, 2026
Peak width of skeletonized mean diffusivity reveals early and multifactorial white matter injury across sporadic and Down syndrome-associated Alzheimer's diseaseAlejandra O Morcillo-Nieto, Maria Franquesa-Mullerat, Sara E Zsadanyi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 29, 2017
Cortical microstructural changes along the Alzheimer's disease continuumVictor Montal, Eduard Vilaplana, Daniel Alcolea, et al.
NPJ Parkinson'S Disease|April 10, 2026
Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein diseaseAlena M Smith, Sara A Lorkiewicz, Burak Arslan, et al.
Nature Aging|April 28, 2023
CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panelsMarta Del Campo, Carel F W Peeters, Erik C B Johnson, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 12, 2025
Development of amyloid-negative neuropsychological norms using GAMLSSSara Rubio-Guerra, María Belén Sánchez-Saudinós, Isabel Sala, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 19, 2022
Intermediate and Expanded HTT Alleles and the Risk for α-SynucleinopathiesSergio Pérez-Oliveira, Ignacio Álvarez, Irene Rosas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 4, 2025
Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stagesMatej Perovnik, Urban Simončič, Jan Jamšek, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 6, 2020
Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patientsLorena Martín-Aguilar, Pol Camps-Renom, Cinta Lleixà, et al.
Journal of Alzheimer'S Disease : JAD|October 16, 2018
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid BiomarkersMafalda Ramos de Matos, Catarina Ferreira, Sanna-Kaisa Herukka, et al.
Pageof 25